Skip to content
DataLookout
Menu

NCT04216290

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 215 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria shortened, about 14 words
    • Secondary endpoints revised (8)
    • Study description revised
    • Site details revised at 17 of 216 sites
  2. Notable Enrollment reduced: 95 → 11 participants
    • Primary completion moved earlier from Jun 30, 2026 to Feb 4, 2026
    • Study completion pushed from Jun 30, 2026 to May 19, 2027
    v214
  3. Study Status, Contacts/Locationsv209
  4. Minor Study sites revised (216)v208
  5. Minor Study sites revised (216)v206
Show 29 earlier versionsHide 29 earlier versions
  1. Minor Study sites revised (216)v205
  2. Minor Study sites revised (216)v204
  3. Minor Study sites: 217 to 216v203
  4. Minor Study sites revised (217)v200
  5. Minor Study sites revised (217)v199
  6. Minor Study sites: 218 to 217v198
  7. Minor Study sites revised (218)v197
  8. Minor Study sites revised (218)v196
  9. Minor Site details revised at 1 of 218 sitesv195
  10. Notable Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 8 of 8 entries
    • Study description expanded, about 28 words
    • Study title shortened, about 1 word
    v192
  11. Minor Study sites revised (218)v191
  12. Minor Study sites revised (218)v190
  13. Minor Study sites revised (218)v189
  14. Minor Study sites revised (218)v188
  15. Minor Study sites revised (218)v186
  16. Minor Study sites revised (218)v184
  17. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 218 of 218 sites
    v181
  18. Notable Start date: Aug 25, 2020 to Mar 17, 2021
    • Site details revised at 1 of 218 sites
    v180
  19. Minor Site details revised at 1 of 218 sitesv179
  20. Minor Site details revised at 1 of 218 sitesv178
  21. Minor Study sites: 217 to 218v176
  22. Minor Site details revised at 1 of 217 sitesv175
  23. Minor Study sites: 216 to 217v174
  24. Minor Site details revised at 1 of 216 sitesv173
  25. Minor Study sites revised (216)v171
  26. Minor Site details revised at 2 of 216 sitesv170
  27. Minor Site details revised at 2 of 216 sitesv169
  28. Minor Site details revised at 1 of 216 sitesv167
  29. Notable Eligibility criteria shortened, about 55 wordsv166 Show 4 more changesShow less
    • Enrollment target: 102 to 95
    • Interventions: Cisplatin (Drug), Durvalumab (Biological), Fluorouracil (Drug), Gemcitabine Hydrochloride (Drug), Mitomycin (Drug), Patient Observation… to Biopsy of Bladder (Procedure), Biospecimen Collection (Procedure), Cisplatin (Drug), Computed Tomography (Procedure), Cystoscopy…
    • Study description expanded, about 101 words
    • Site details revised at 1 of 216 sites
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Clinical Complete Response
Timeframe: Assessed at baseline, every 12 weeks for 2 years, every 6 months for year 3 and annually for year 4

Secondary (8)

Treatment-related Grade 3 or Higher Adverse Event Rate
Progression-free Survival (PFS)
Duration of Complete Response
1-year Overall Survival (OS) Rate
Bladder Intact Event Free Survival (BIEFS)
Show 3 moreShow less
Metastasis-free Survival (MFS)
1-year Bladder Cancer-specific Survival Rate
Salvage Cystectomy Rate

Arms and interventions

Step 1, Arm C (durvalumab, radiation therapy, chemotherapy)Experimental

Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

Step 1, Arm D (radiation therapy, chemotherapy)Active comparator

Patients undergo radiation therapy for 6.5-8 weeks. Beginning 4 days before or after starting radiation therapy, patients also receive gemcitabine hydrochloride IV over 30-60 minutes BIW for 6 weeks; or cisplatin IV over 30-60 minutes QW for 6 weeks; or mitomycin IV over 30 minutes on day 1 of radiation and fluorouracil IV continuous infusion on days 1-5 and 16-20 of radiation in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

Step 2, Arm E (durvalumab)Experimental

Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

Step 2, Arm F (observation)Active comparator

Patients previously randomized to Arm D (chemoradiation) who achieve clinical CR or clinical benefit undergo observation undergo observation. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.

Procedures: Biopsy of Bladder, Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging

Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Mitomycin

Biologicals: Durvalumab

Other: Patient Observation

Radiation: Radiation Therapy

Sites

216 sites in 1 country